Genetic variants in TAP are associated with high-grade cervical neoplasia

Clinical Cancer Research

Volumn 15, Issue 3, 2009, Pages 1019-1023

  Einstein, Mark H ^a,b,c   Leanza, Suzanne ^a   Chiu, Lydia G ^a   Schlecht, Nicolas F ^a,b   Goldberg, Gary L ^a,b,c   Steinberg, Bettie M ^d   Burk, Robert D ^a,b,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b ALBERT EINSTEIN CANCER CENTER   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

^d LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE SEQUENCE; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; SINGLE NUCLEOTIDE POLYMORPHISM; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; WART VIRUS;

ATP-BINDING CASSETTE TRANSPORTERS; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; PAPILLOMAVIRUS INFECTIONS; POLYMORPHISM, GENETIC; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 61349118779     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1207     Document Type: Article

References (24)

1. Wheeler CM, Parmenter CA, Hunt WC, et al. Determinants of genital human papillomavirus infection amongcytologically normal women attending the University of New Mexico student health center. Sex Transm Dis 1993;20:286-9.
2. Burk RD, Kelly P, Feldman J, et al. Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. Sex Transm Dis 1996;23:333-41.
3. Bauer HM, Hildesheim A, Schiffman MH, et al. Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon. Sex Transm Dis 1993;20:274-8.
4. Fruh K, Ahn K, Djaballah H, et al. A viral inhibitor of peptide transporters for antigen presentation. Nature 1995;375:415-8.
5. Bonagura VR, Siegal FP, Abramson AL, et al. Enriched HLA-DQ3 phenotype and decreased class I major histocompatibility complex antigen expression in recurrent respiratory papillomatosis. Clin Diagn Lab Immunol 1994;1:357-60.
6. Cromme FV, Airey J, Heemels MT, et al. Loss of transporter protein, encoded by theTAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 1994;179:335 -40.
7. Cromme FV, Snijders PJ, van den Brule AJ, Kenemans P, Meijer CJ, Walboomers JM. MHC class I expression in HPV 16 positive cervical carcinomas is post-transcriptionally controlled and independent from c-myc overexpression. Oncogene1993;8:2969 -75.
8. Heemels MT, Ploegh H. Generation, translocation, and presentation of MHC class I-restricted peptides. Annu Rev Biochem 1995;64:463 -91.
9. Engelhard VH. How cells process antigens. Sci Am 1994;271:54-61.
10. Burgert HG, Kvist S. The E3/19K protein of adenovirus type 2 binds to the domains of histocompatibility antigens required for CTL recognition. EMBO J 1987;6:2019-26.
11. Vandevyver C, Geusens P, Cassiman JJ, Raus J. Peptide transporter genes (TAP) polymorphisms and genetic susceptibility to rheumatoid arthritis. Br J Rheumatol 1995;34:207 -14.
12. Faucz FR, Probst CM, Petzl-Erler ML. Polymorphism of LMP2, TAP1, LMP7 and TAP2 in Brazilian Amerindians and Caucasoids: implications for the evolution of allelic and haplotypic diversity. Eur J Immunogenet 2000;27:5-16.
13. Lankat-Buttgereit B, Tampe R. The transporter associated with antigen processing: function and implications in human diseases. Physiol Rev 2002;82:187 -204.
14. Abadi MA, Ho GY, Burk RD, Romney SL, Kadish AS. Stringent criteria for histological diagnosis of koilocytosis fail to eliminate overdiagnosis of human papillomavirus infection and cervical intraepithelial neoplasia grade1. Hum Pathol 1998;29:54-9.
15. Ho GY, Palan PR, Basu J, et al. Viral characteristics of human papillomavirus infection and antioxidant levels as risk factors for cervical dysplasia. Int J Cancer1998;78:594-9.
16. Burk RD, Spitzer C. Genetic screening with exfoliated cervicovaginal cells collected by a noninvasive lavage technique performed during routine gynecologic cancer screening. Am J Obstet Gynecol 1990;162:652-4.
17. Connor ME, Stern PL. Loss of MHC class-I expression in cervical carcinomas. Int J Cancer 1990;46:1029 -34.
18. Ritz U, Momburg F, Pilch H, Huber C, Maeurer MJ, Seliger B. Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol 2001;19:1211 -20.
19. Tao J, Zhang XP, Chen XP, et al. Local expression of TAP-1 and MHC-I molecules and their relationship in condyloma acuminatum. Clin Exp Dermatol 2007;32:550-5.
20. Keating PJ, Cromme FV, Duggan-Keen M, et al. Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer 1995;72:405 -11.
21. Gostout BS, Poland GA, Calhoun ES, et al. TAP1, TAP2, and HLA-DR2 alleles are predictors of cervical cancer risk. Gynecol Oncol 2003;88:326 -32.
22. Cao B, Tian X, Li Y, et al. LMP7/TAP2 gene polymorphisms and HPV infection in esophageal carcinoma patients from a high incidence area in China. Carcinogenesis 2005;26:1280-4.
23. Fowler NL, Frazer IH. Mutations in TAP genes are common in cervical carcinomas. Gynecol Oncol 2004;92:914-21.
24. Mehta AM, Jordanova ES, van Wezel T, et al. Genetic variation of antigen processing machinery components and association with cervical carcinoma. Genes Chromosomes Cancer 2007;46:577 -86.